Hyaluronic Acid in Shoulder Tendinopathy

Inclusion Criteria:

• Active patient aged between 18 and 65;

• Patient suffering from pain compatible with supraspinatus tendinopathy for at least 2 months;

• Patient with simple tendinopathy or partial tendon rupture;

• Patient with tendinopathy confirmed by ultrasound or MRI;

• Patient with an active pain visual analog scale ≥ 4 for more than 6 weeks;

• Patient with an active pain visual analog scale ≥ 4 on the day of inclusion;

• Patient failing medical treatment (rest, analgesics, NSAIDs, physiotherapy);

• Patient able to follow the protocol and having given oral informed consent to takepart in the research;

• Patient affiliated to the social security system or entitled person;

Exclusion Criteria:

• Patient suffering from a transfixing tendon rupture;

• Patients suffering from post-traumatic tendon rupture;

• Patients suffering from calcific tendinopathy (calcification > 5 mm);

• Patients with associated glenohumeral osteoarthritis;

• Patients with associated symptomatic acromioclavicular osteoarthritis;

• Patients with shoulder pain for reasons other than tendinopathy (capsulitis, chronicinflammatory rheumatism, fibromyalgia, amyloidosis);

• Patients who have had a subacromial infiltration in the previous 6 months;

• Patients with a known allergy to one of the products including their excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol);

• Patients with a known allergy to lidocaine;

• Patients with a local or generalised infection, or suspected infection;

• Patients with severe coagulation disorders or taking anticoagulants;

• Patients with severe and/or uncontrolled hypertension > 160/100 mmHg;

• Patients with unbalanced diabetes (last HbA1c > 8.5%);

• Patients with a history of addiction to psychoactive substances;

• Patient participating in another clinical research protocol with an impact on theresearch objectives;

• Patient already randomised in the study;

• Patient who is pregnant, parturient, breastfeeding or able to procreate withouteffective contraception* in the month prior to inclusion and up to 15 days afterinfiltration;

• Patients under guardianship, curators or deprived of liberty;

• Patient under a mandate for future protection activated ;

• Patient under family guardianship ;

• Patient under court protection ;